Celyad announces third quarter 2016 business update

Celyad announces third quarter 2016 business update

Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa

Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa

Celyad appoints Philippe Dechamps as General Counsel and Company Secretary

Celyad appoints Philippe Dechamps as General Counsel and Company Secretary

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1): Clinical Trial Primary Outcomes

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1): Clinical Trial Primary Outcomes

Celyad Reports First Half 2016 Financial Results and Operational Progress

Celyad Reports First Half 2016 Financial Results and Operational Progress

Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immunotherapy

Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immunotherapy

Celyad appoints Graham Morrell as Vice-President of Investors Relations & Communication

Celyad appoints Graham Morrell as Vice-President of Investors Relations & Communication

Celyad appoints Dr. David Gilham as Vice-President of Research & Development

Celyad appoints Dr. David Gilham as Vice-President of Research & Development

Celyad announces first quarter 2016 business update

Celyad announces first quarter 2016 business update

Celyad will present its NKR-2 immuno-oncology clinical program at 2016 ASCO Annual Meeting

Celyad will present its NKR-2 immuno-oncology clinical program at 2016 ASCO Annual Meeting

Celyad appoints leading international Immuno-Oncology experts to Scientific Advisory Board

Celyad appoints leading international Immuno-Oncology experts to Scientific Advisory Board

Celyad reports 2015 Financial and Operating results

Celyad reports 2015 Financial and Operating results